Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases.

Journal of controlled release : official journal of the Controlled Release Society - 28 Nov 2017

Suda Kenji, Murakami Tatsuya, Gotoh Norimoto, Fukuda Ryosuke, Hashida Yasuhiko, Hashida Mitsuru, Tsujikawa Akitaka, Yoshimura Nagahisa

Abstract excerpt

Age-related macular degeneration (AMD), in which choroidal neovascularization (CNV) affects the center of the retina (macula), leads to the irreversible visual loss. The intravitreal injection of anti-angiogenesis antibodies improved the prognosis of AMD, but relatively less invasive therapies should be explored. In the present study, we show that a high-density lipoprotein (HDL) mutant is a therapeutically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Choroidal Neovascularization

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coumarins

Share to Drug Carriers

Share to Indazoles

Share to Lipoproteins, HDL

Share to Liposomes

Share to Nanoparticles

Source

Identifiers

PMID: 28987881
DOI: 10.1016/j.jconrel.2017.09.036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases.PMID 28987881Read ↗

Advancements in Neovascular Ophthalmopathy: Therapeutic Strategies and Future ProspectsSemantic proximity Read ↗

Engineered virus-like particle-assembled VEGF-targeting Cas9 ribonucleoprotein treatment alleviates neovascularization in wet age-related macular degenerationSemantic proximity Read ↗

Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration.Semantic proximity Read ↗

Self-assembled nanoparticles enable delivery of VCP inhibitor, resulting in enhanced photoreceptor protection in retinal explantsSemantic proximity Read ↗

Intraocular RGD-Engineered Exosomes and Active Targeting of Choroidal Neovascularization (CNV)Semantic proximity Read ↗

Gene therapy in age related macular degeneration and hereditary macular disordersSemantic proximity Read ↗

Recent Advances in Glaucoma Pharmacotherapy: A State-of-the-Art Review on Next-Generation Compounds and Delivery TechnologiesSemantic proximity Read ↗

GB10, a best-in-class antibody fusion protein targeting VEGF/Ang-2, exhibits promising therapeutic efficacy for neovascular eye diseasesSemantic proximity Read ↗

Laser-induced choroidal neovascularization model to study age-related macular degeneration in miceSemantic proximity Read ↗

Lipid-stabilized ICG Nanoaggregates for the Photodisruption of Vitreous OpacitiesSemantic proximity Read ↗

Thrombospondin-1 proteomimetic polymers exhibit anti-angiogenic activity in a neovascular age-related macular degeneration mouse modelSemantic proximity Read ↗

The Past, Present, and Future Perspective of Photodynamic Therapy for Age-Related Macular DegenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.